OUR MISSION
Biologics discovery needs more than generic AI
AI-guided design holds enormous promise for accelerating development pipelines. However, most models are not designed to address the developability, manufacturability, or stability issues behind most drug candidate failures.
Built by the scientists behind 20+ FDA-approved therapies, EMLy Co-pilot addresses this gap.
Compress discovery from weeks to minute
EMLy helps you move faster by orchestrating models, datasets, and computational resources so you can focus on your science.
Turn conversation into actionable science
Through a simple yet scientifically fluent chat interface, EMLy transforms your questions into high-impact, design-ready outputs.
Built to adapt to real therapeutic challenges
Grounded in rich immunological data and experimental validation, EMLy can help you explore multiple modalities (mAbs, TCRs, and more!)
OUR TECHNOLOGY
Underpinned by powerful, validated computational capabilities
Proprietary structural modeling
Evaluate structural elements associated with therapeutic function and efficacy
Variant generation
Enables iterative thinking and design branching to produce variants in minutes
Biologics optimisation
Engineers molecules for improved stability, expression, and manufacturability
Machine learning
model development
Scans through immune datasets to learn the ‘language’ of effective immune motifs
OUR MOTIVATION
For teams building the next generation of biologics
From nimble seed-stage biotechs to global R&D organisations, EMLy gives scientists access to advanced AI-driven biologics discovery, without requiring specialized computational expertise.
Clinical
Lead
optimization
& CMC
Hit-to-lead
Target-to-hit
Target hypothesis
Custom workflow:
Proprietry immune sequencing.
Custom workflow:
Functional immune discovery.
Biologics and small molecule drugs.
Co-complex prediction.
Custom workflow:
Antibody expression enhancement.
